224309-64-2

Basic information

• Product Name: 4-N-BOC-AMINO-CYCLOHEXANOL
• Synonyms: 4-N-BOC-AMINO-CYCLOHEXANOL;(4-HYDROXY-CYCLOHEXYL)-CARBAMIC ACID TERT-BUTYL ESTER;Carbamic acid, (4-hydroxycyclohexyl)-, 1,1-dimethylethyl ester (9CI);N-4-Boc-aminocyclohexanol;4-[(tert-Butoxycarbonyl)amino]cyclohexanol (Mixture of Diastereomers);4-(Boc-amino)cyclohexanol;tert-Butyl 4-hydroxycyclohexylcarbaMate;CarbaMic acid, N-(4-hydroxycyclohexyl)-, 1,1-diMethylethyl ester
• CAS NO: 224309-64-2
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Product Categories: N-BOC;Amines;blocks;Intermediates;Miscellaneous Reagents
• Mol File: 224309-64-2.mol
• Article Data: 22

Chemical Properties

• Melting Point: 170.0 to 174.0 °C
• Boiling Point: 337.7 °C at 760 mmHg
• Flash Point: 158 °C
• Appearance: /
• Density: 1.06 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, Dichloromethane, DMSO, Methanol
• PKA: 12.36±0.40(Predicted)
• CAS DataBase Reference: 4-N-BOC-AMINO-CYCLOHEXANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-BOC-AMINO-CYCLOHEXANOL(224309-64-2)
• EPA Substance Registry System: 4-N-BOC-AMINO-CYCLOHEXANOL(224309-64-2)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-50
• Safety Statements: 61
• Hazardous Substances Data: 224309-64-2(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Synthesis Reference(s)

Chemistry Letters, 22, p. 1273, 1993Tetrahedron Letters, 33, p. 2677, 1992 DOI: 10.1016/S0040-4039(00)79055-1

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 6850-65-3 p-hydroxycyclohexylamine 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 27489-62-9 trans-4-hydroxycyclohexylamine 

Downstream Products

• 1448310-30-2 cis-(t-butoxy)-N-(4-fluorocyclohexyl)carboxamide 
• 1246533-50-5 C₁₃H₂₅NO₃ 
• 675112-67-1 tert-butyl (4,4-difluorocyclohexyl)carbamate 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 1404059-56-8 tert-butyl {3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}carbamate 
• 1404059-57-9 8-amino-3-[2-(4-fluorophenoxy)ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione 
• 1404059-58-0 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-3,4-dimethyl benzenesulfonamide 
• 1404059-59-1 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-2-methylbenzene sulfonamide 
• 1404059-61-5 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-2-fluobenzene sulfonamide 
• 1404059-62-6 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-2,5-dimethyl benzenesulfonamide 
• 1404059-63-7 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-4-methylbenzene sulfonamide 
• 1404059-64-8 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-3-chlorobenzene sulfonamide 
• 1404059-65-9 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-4-fluoro-2-methyl benzenesulfonamide 
• 1404059-66-0 N-{3-[2-(4-fluorophenoxy)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]dec-8-yl}-4-methoxybenzene sulfonamide 

Relevant articles and documents

LIPID NANOPARTICLE COMPOSITION

Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination.

Design, synthesis, and biological evaluation of radioiodinated benzo[d]imidazole-quinoline derivatives for platelet-derived growth factor receptor β (PDGFRβ) imaging

Several malignant tumors and fibrotic diseases are associated with PDGFRβ overexpression and excessive signaling, making this receptor attractive for molecular targeting and imaging approaches. A series of benzo[d]imidazole-quinoline derivatives were designed and synthesized to develop radioiodinated compounds as PDGFRβ-specific imaging probes. The structure activity relationship (SAR) evaluation of the designed compounds was performed. Among them, 2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]-8-(piperazin-1-yl)quinoline (5a) and 4-{2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}morpholine (5d) exhibited a relatively high PDGFRβ-TK inhibitory potency, whereas iodinated 5a derivative 5-iodo-2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]-8-(piperazin-1-yl)quinoline (8) exhibited a superior inhibitory potency as PDGFRβ inhibitor than iodinated 5d derivative 4-{5-iodo-2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}morpholine (11). Furthermore, [125I]8 and [125I]11 were synthesized and evaluated for PDGFRβ radioligand ability, both in vitro and in vivo. Cellular uptake experiments showed that [125I]8 had a higher uptake in BxPC3-luc cells as PDGFRβ-positive cells than [125I]11. Incubation of [125I]8 after pretreatment of PDGFRβ ligands significantly reduced the uptake of [125I]8. In biodistribution experiments using tumor-bearing mice, [125I]8 accumulation in the tumor 1 h postinjection was higher than that of the benzo[d]imidazol-quinoline derivative [125I]IIQP, used in our previous research. These results indicate that [125I]8 could be a promising PDGFRβ imaging agent. Although its clinical application requires further structural modifications, the results obtained in this research may be useful for the development of PDGFRβ-specific radioligands.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I: in which n, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a pro